[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Huang GW, Yang LY: Metallothionein expression in hepatocellular carcinoma. World J Gastroenterol; 2002 Aug;8(4):650-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein expression in hepatocellular carcinoma.
  • AIM: To investigate the expression of metallothioneins (MTs), which were recently thought to have close relationship with tumors, in human hepatocellular carcinoma.
  • METHODS: Histological specimens of 35 cases of primary human hepatocellular carcinoma with para-neoplastic liver tissue and 5 cases of normal liver were stained for MTs with monoclonal mouse anti-MTs serum (E9) by the immunohistochemical ABC technique.
  • But MTs were stained strongly positive in all the five cases of normal liver and 35 cases of para-neoplastic liver tissue.
  • The differences of MTs expression between HCC and normal liver tissue or para-neoplastic liver tissue were highly significant (P<0.01).
  • The rate of MTs expression in HCC grade I was 100 percent, higher than that in grade II(81 %) and grade III and IV (78 %).
  • No obvious correlations between MTs expression in HCC and tumor size, clinical stage or serum alpha fetoprotein concentration were found (P>0.05).
  • We can choose the anticancer agents according to the MTs concentration in HCC, which may improve the results of chemotherapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. Metallothionein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174372.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  • [Other-IDs] NLM/ PMC4656314
  •  go-up   go-down


2. Park KW, Park JW, Cho SH, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Kim DY, Hong EK, Kim CM: [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. Korean J Hepatol; 2006 Mar;12(1):41-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities].
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is 3rd leading cause of cancer in Korea and the prognosis for HCC patients is poor.
  • For assessing the present treatment outcome, this study analyzed the three-year survival rate (3-YSR) and the prognostic factors for patients with HCC in Korea.
  • The overall 3-YSR of the patients with modified UICC stage I, II, III, IVa and IVb were 67.4%, 65.2%, 30.7%, 9.0% and 5.0%, respectively.
  • The modified UICC stage could not differentiate stage I from II, and stage IVa from IVb, on the 3-YSR.
  • The 3-YSR of the Child-Pugh class A patients with modified UICC stage I or II was 85.4% by surgical resection and it was 69.6% by transcatheter chemoembolization (TACE), respectively (P= .461), and those values for patients with stage III were 49.2% and 36.8%, respectively (P=.081).
  • As compared with systemic chemotherapy or conservative therapy, TACE increased the survival rate more for the Child-Pugh class A patients with stage IV.
  • The independent prognostic factors were serum AFP, portal vein thrombosis, the Child-Pugh classification and the stage of HCC.
  • CONCLUSIONS: This follow-up study will be helpful in assessing the results of treatments for HCC and it will provide data for the establishment of a more effective treatment strategy.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565605.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC: Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer; 2003 Apr 15;97(8):2006-12
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrolamellar hepatocellular carcinoma in children and adolescents.
  • BACKGROUND: Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC.
  • After undergoing initial surgery or biopsy, children with Stage I HCC (n = 8 patients), Stage III HCC (n = 25 patients), and Stage IV HCC (n = 13 patients) were assigned randomly, regardless of histology, to receive treatment either with cisplatin, vincristine, and fluorouracil (n = 20 patients) or with cisplatin and continuous-infusion doxorubicin (n = 26 patients).
  • There was no difference in the number of patients with advanced-stage disease, the incidence of surgical resectability at diagnosis, or the response to treatment between patients with FL-HCC and patients with typical HCC.
  • CONCLUSIONS: Children with FL-HCC do not have a favorable prognosis and do not respond any differently to current therapeutic regimens than patients with typical HCC.
  • Children with initially resectable HCC have a good prognosis irrespective of histologic subtype, whereas outcomes are poor uniformly for children with advanced-stage disease.
  • The use of novel chemotherapeutic agents and the incorporation of other treatment modalities are indicated to improve the dismal survival of pediatric patients with all histologic variants of advanced-stage HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cisplatin / administration & dosage. Cohort Studies. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Hepatoblastoma. Humans. Infant. Infusions, Intravenous. Male. Neoplasm Staging. Prognosis. Prospective Studies. Risk Factors. Time Factors. Treatment Outcome. Vincristine / administration & dosage. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12673731.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 36
  •  go-up   go-down


Advertisement
4. Gervain J: [Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening]. Orv Hetil; 2010 Aug 29;151(35):1415-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening].
  • [Transliterated title] A hepatocellularis carcinoma tünetei. A diagnosztika és a szurés laboratóriumi vizsgálatai.
  • Early stage hepatocellular carcinoma is a symptom-free disease.
  • Local and general symptoms occur due to the growth of the tumor tissue and the infiltration of the surrounding blood vessels.
  • Illness progression is indicated by the development of abdominal discomfort, cachexia, therapy-resistant decompensation of previously compensated cirrhosis and in severe cases, the thrombosis of the portal vein or the hepatic veins.
  • To clarify the etiology and to identify high risk patients, we need to differentiate alcohol-, drug- or chemical-induced hepatic disorders, viral hepatitis B, C and Delta, metabolic disorders and non-alcoholic steatohepatitis.
  • Other, less commonly measured biomarkers are the glycosilated alfa fetoprotein-L3 and the vitamin K-deficiency induced des-gamma-carboxy prothrombin.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / prevention & control. Liver Neoplasms / diagnosis. Liver Neoplasms / prevention & control. Mass Screening / methods
  • [MeSH-minor] Alcohol Drinking / adverse effects. Biomarkers / blood. Drug-Induced Liver Injury / complications. Early Detection of Cancer. Fatty Liver / complications. Hepatitis, Viral, Human / complications. Humans. Protein Precursors / blood. Prothrombin. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719715.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


5. Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, Uehara K, Inayoshi J, Yokoyama J, Ishimoto Y, Asakura H: Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol; 2001 Apr;16(4):452-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma.
  • BACKGROUND AND AIMS: There is currently no proven chemotherapy regimen for hepatocellular carcinoma (HCC).
  • The principal chemotherapeutic approach in most cases is infusion therapy into the hepatic arteries feeding the tumors.
  • However, the clinical effects of chemotherapy are extremely poor.
  • METHODS: From 1994 to 1999, a total of 56 consecutive patients with unresectable stage IV-A HCC were studied prospectively to examine the efficacy of enteric-coated tegafur/uracil in HCC and to determine the significant prognostic factors.
  • Twenty-eight patients were treated only with enteric-coated tegafur/uracil without other anticancer treatment.
  • RESULTS: In the group treated only with enteric-coated tegafur/uracil, the median survival time and 1 and 2 year survival rates were 12.13 months and 55.3 and 36.9%, respectively.
  • In the control group, the median survival time and 1 year survival rate were 6.20 months and 5.5%, respectively.
  • By both univariate analysis and multivariate analysis using Cox's proportional hazards model, treatment with enteric-coated tegafur/uracil was shown to be the factor most significantly favoring a better prognosis.
  • CONCLUSIONS: Although the prognosis of most patients with stage IV-A HCC is poor, administration of enteric-coated tegafur/uracil induces long-term survival and is an effective treatment for stage IV-A HCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Analysis. Tablets, Enteric-Coated

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2001 Apr;16(4):361-2 [11354272.001]
  • (PMID = 11354285.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Tablets, Enteric-Coated; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


6. Homma H, Mezawa S, Doi T, Miyanishi K, Takada K, Kukitsu T, Oku T, Masuko E, Nojiri S, Niitsu Y: A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Hepatogastroenterology; 2004 Jul-Aug;51(58):1135-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV).
  • BACKGROUND/AIMS: The study was performed to investigate the anti-tumor effect, survival rate, and toxicity of intermittent intrahepatic infusion chemotherapy with carboplatin suspended in lipiodol.
  • METHODOLOGY: We conducted a randomized controlled study containing either doxorubicin or carboplatin in 65 patients with advanced hepatocellular carcinoma.
  • Therefore, carboplatin is effective and preferable for repeated intrahepatic arterial administration to treat advanced hepatocellular carcinoma over a relatively long period.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / administration & dosage. Liver Neoplasms / drug therapy
  • [MeSH-minor] Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Combinations. Emulsions. Female. Humans. Infusions, Intra-Arterial. Iodized Oil / administration & dosage. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239261.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Emulsions; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin
  •  go-up   go-down


7. Chia WK, Ong S, Toh HC, Hee SW, Choo SP, Poon DY, Tay MH, Tan CK, Koo WH, Foo KF: Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore; 2008 Jul;37(7):554-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.
  • INTRODUCTION: Advanced hepatocellular carcinoma (HCC) has a dismal prognosis and is notoriously chemo-resistant.
  • We conducted a Phase II prospective study to evaluate the activity and tolerability of gemcitabine and cisplatin in chemo-naïve advanced hepatocellular carcinoma.
  • Utilising a Simon's minimax two-stage design with a type I error of 0.05 and power of 80%, 25 subjects would be required.
  • Fifteen patients would be needed in stage 1 and if fewer than 2 responses were observed, the trial would be stopped and lack of efficacy claimed.
  • Assessment of response based on computer tomography was performed after every 2 cycles of chemotherapy.
  • This regime was well tolerated and there was only 1 patient who experienced grade IV toxicities.
  • A further 3 patients experienced stable disease and 11 patients progressed on chemotherapy.
  • The median time to progression was 6 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695766.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Lee GY, Kim BS, Seo YT, Choi SH, Kim HJ, Choi DS, Ko JY, Yang SH, Byun JH: Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma. Korean J Intern Med; 2003 Jun;18(2):104-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma remains a highly chemoresistant neoplasm and is a common malignancy with poor prognosis in Korea.
  • We performed a phase II study to evaluate the efficacy and toxicities of topotecan and cisplatin combination chemotherapy for advanced hepatocellular carcinoma.
  • METHODS: Between November 1999 and May 2001, ten patients with histologically proven hepatocellular carcinoma were enrolled in this study.
  • Six patients demonstrated stage IV, 1 stage IIIC, 2 stage IIIB and 1 stage IIIA.
  • The treatment regimen consisted of topotecan 1.25 mg/m2 and cisplatin 20 mg/m2 for 5 days.
  • The treatment was repeated every 4 weeks.
  • But there was no treatment-related death.
  • CONCLUSION: When used in this dose and schedule, topotecan and cisplatin combination chemotherapy does not seem to be effective for patients with advanced hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Cisplatin / administration & dosage. Liver Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872448.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC4531618
  •  go-up   go-down


9. Kamiyama T, Nakagawa T, Nakanishi K, Kurauchi N, Kamachi H, Matsushita M, Todo S: [Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1618-20
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma].
  • Postoperative adjuvant intraarterial infusion chemotherapy was performed for 22 hepatectomized patients with Stage III and Stage IV-A hepatocellular carcinoma from July, 1997, to December, 1999.
  • One course of this chemotherapy consisted of cisplatin (10 mg/body/day on days 1-5) followed by 5-FU (250 mg/body/day on days 1-5).
  • One hundred forty-eight patients of Stage III and Stage IV-A underwent hepatectomy from 1992 to 2001 and were enrolled as historical control.
  • There were 9 Stage III cases treated with this adjuvant chemotherapy, and there were 7 or 6 Stage IV-A cases with and without main portal thrombosis, respectively.
  • Survival and disease-free survival curves were not improved compared to historical control by this adjuvant chemotherapy.
  • The number of recurrences in the remnant liver of 2 Stage IV-A cases with main portal thrombosis was limited to 3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatectomy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Postoperative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619478.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


10. Xiong ZP, Zhang YD, Huang F, Liang ZY: [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Aug;29(8):623-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the efficiency and safety of transhepatic arterial chemoembolization (TACE) with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma (HCC).
  • The toxicity and hepatic damage were observed according to WHO anticancer drug toxicity criteria and Child-Pugh classification criteria, respectively.
  • The survival time was also observed during follow-up.
  • RESULTS: The blood toxicity was bone marrow suppression presented as grade I leucopenia in 39.3%, grade II in 29.5%, grade III-IV in 18.0%.
  • Grade II-III nausea and vomiting developed in 96.8% of the patients.
  • The median survival time was 20 months with a range of 5 to 3 5 months.
  • CONCLUSION: Transhepatic arterial chemoembolization using carboplatin and mixture of gemcitabine with ultra-lipoidal iodide oil emulsion is safe and effective in the management of stage III hepatocellular carcinoma.
  • [MeSH-major] Carboplatin / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Deoxycytidine / analogs & derivatives. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210886.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


11. Nakamura H, Kawata S, Takamura M, Osuga K, Murakami T: [Transcatheter arterial embolization for advanced hepatocellular carcinoma--indications and limitations]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1509-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transcatheter arterial embolization for advanced hepatocellular carcinoma--indications and limitations].
  • Many patients with advanced hepatocellular carcinoma (HCC) in stage IV have no surgical indications.
  • Transcatheter methods such as transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy play a main role of the treatment for advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11015994.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


12. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A: Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol; 2000 Aug;12(8):941-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation.
  • BACKGROUND AND AIMS: The aetiology of chronic liver disease leading to hepatocellular carcinoma (HCC) and the clinical characteristics at the time of presentation vary considerably among different parts of the world and over time.
  • We investigated baseline characteristics of patients with hepatocellular carcinoma such as cirrhosis, hepatitis virus markers, age at presentation and stage of the tumour in an area with low prevalence of viral hepatitis.
  • RESULTS: The median age at detection of HCC was 63.3 years, and alcoholic liver disease (35.1%) and hepatitis C virus (HCV) infection (36.7%) were the most frequent underlying diseases.
  • At the time of diagnosis, 43.5% had multi-nodular tumours.
  • Most of our patients presented at a late stage of the disease (TNM stage 3 29.4%, TNM stage 4 69.7%; Okuda stage 2 65.7%, Okuda stage 3 18.0%).
  • Due to the late stage of the disease at the time of presentation, 145 patients (59.2%) received palliative care only, 24 (9.8%) underwent liver resection, 38 (15.5%) liver transplantation and 38 (15.5%) chemotherapy.
  • This resulted in a high percentage of patients who received palliative care only and very few who were eligible for treatment modalities with curative potential such as resection and liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Liver Cirrhosis / complications. Liver Cirrhosis / diagnosis. Liver Neoplasms / diagnosis. Liver Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10958223.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


13. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, Sata M: Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol; 2003 Nov;181(5):1327-34
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
  • OBJECTIVE: The prognosis of advanced hepatocellular carcinoma remains poor.
  • The aim of this study was to compare the efficacy of hepatic artery infusion chemotherapy and transcatheter arterial Lipiodol chemoembolization for treatment of advanced tumor.
  • Thirty-seven patients with hepatocellular carcinoma and unresectable tumors were enrolled.
  • In the hepatic artery infusion chemotherapy group (n = 16), cisplatin (10 mg/person, on days 1-5) and subsequent 5-fluorouracil (250 mg/person, on days 1-5) were administered for four serial courses.
  • RESULTS: The tumor response rates (complete response plus partial response for all cases) of the hepatic artery infusion chemotherapy and transcatheter arterial Lipiodol chemoembolization groups were 56.3% and 23.8%, respectively, showing the significantly higher rate in the former than in the latter group.
  • The cumulative survival rates between the two groups were not significantly different; whereas in those patients whose tumors were classified as TNM stage IV or as having the maximal tumor size of greater than 5 cm, patients tended to have higher survival rates in the hepatic artery infusion chemotherapy group than in the transcatheter arterial Lipiodol chemoembolization group.
  • Patients' adverse reactions were successfully managed by treatment of symptoms.
  • CONCLUSION: Hepatic artery infusion chemotherapy had a better antitumor effect than transcatheter arterial Lipiodol chemoembolization and may be a useful therapeutic option for more advanced hepatocellular carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Radiography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Cisplatin / administration & dosage. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Iodized Oil / administration & dosage. Male. Middle Aged. Statistics, Nonparametric. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14573429.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Rasila K, Lee FC, Rabinowitz I: A phase II trial of thalidomide, α-Interferon +/-octreotide in patients with advanced hepatocellular carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4272

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of thalidomide, α-Interferon +/-octreotide in patients with advanced hepatocellular carcinoma.
  • : 4272 Background: Based on clinical efficacy observed in single agent phase II trials, we conducted a novel chemotherapeutic trial with a regimen consisting of thalidomide, α-interferon +/- octreotide for advanced hepatocellular carcinoma.
  • METHODS: Eligibility criteria included histologically proven unresectable or metastatic HCC, measurable disease, ECOG PS ≤ 2, age ≥ 18 yrs, may have had prior systemic or intra hepatic chemotherapy with other agents except the 3 study drugs, may have had previous surgery or regional therapy, adequate hematologic, renal and hepatic function, and informed consent.
  • Treatment consisted of thalidomide initiated at 200 mg/day and increased up to 800 mg/day as tolerated, α-interferon 3 MU subcutaneous three times a week and octreotide 30 mg every month added for patients who had a positive octreotide scan.
  • 50% of the patients were stage III and 50% were stage IV; 66.7% were anti-HCV positive; 83.3% had positive octreotide scans; 5/6 (83.3%) patients had not received any prior chemotherapy (systemic or intrahepatic).
  • 1 patient received prior chemotherapy with single agent doxorubicin.
  • Treatment was stopped in 4 patients due to disease progression, and 1 withdrew because of toxicities.
  • Treatment was well tolerated with only 2 episodes of grade III/IV toxicity comprising neutropenia (n=1) and fatigue (n=1).
  • Median survival after enrollment was 5 months (range 4-21 months) and the median time to progression was 2 months (range 1-4 months).
  • CONCLUSION: Although demonstrating a favorable toxicity profile, combination chemotherapy with Thalidomide,α-Interferon +/- Octreotide has little activity in the treatment of advanced hepatocellular carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015052.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hsu C, Lin Z, Lee K, Yeh K, Hsiao C, Shen Y, Chang D, Wang S, Hsu C, Cheng A: A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report. J Clin Oncol; 2009 May 20;27(15_suppl):e15533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report.
  • Metronomic chemotherapy has been shown to have anti-angiogenic and anti-cancer effect in preclinical and clinical models.
  • This study evaluated the efficacy and safety of the combination of T and metronomic UFT as first-line therapy for advanced HCC.
  • METHODS: Patients (Pts) with advanced HCC not treatable by surgery or other loco-regional therapies received T 100mg bid and UFT 125mg/m<sup>2</sup> (based on tegafur) bid continuously.
  • Treatment was continued in the absence of disease progression or unacceptable toxicity.
  • Baseline characteristics were HBsAg(+)/anti-HCV(+)/both(+) /both(-) 31/6/1/7; AJCC stage II/III/IV 2/18/23; BCLC stage B/C 1/42; CLIP score ≤3/4 27/16; portal vein thrombosis 65%; extrahepatic metastasis 58%; prior local treatment 72%.
  • Grade 3 leucopenia developed in 1 (2.3%) pt.
  • The most common treatment-related grade 3 non-hematologic toxicities were somnolence (n=4, 9.3%), GI bleeding (n=3, 7.0%), and elevated transaminase (n=2, 4.7%).
  • CONCLUSIONS: The combination of T with metronomic UFT is a well-tolerated regimen with moderate activity for advanced HCC, and worth further exploration in pts with CLIP score ≤3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Falcon-Lizaraso S, Leon Chong J, Perazzo F, Goldwasser F, Cohn A, Kahatt C, Weems G, Eckhardt SG: Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results. J Clin Oncol; 2004 Jul 15;22(14_suppl):4083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results.
  • Currently available chemotherapy offers limited benefit to HCC pts.
  • An every 2 weeks schedule has been developed (AACR-NCI-EORTC 2001, abst 214).
  • METHODS: A multicenter phase II trial was initiated to evaluate the objective response rate (RECIST) in HCC pts receiving 0.55 mg/kg IROF (total dose ≤50 mg), as a 30 min IV infusion, days 1 and 15 every 28 days.
  • Eligibility criteria include unresectable HCC, ECOG PS 0-1, and ≤1 prior therapy (chemotherapy included); 29 evaluable pts were to be included in a first stage of accrual with a total of 38 evaluable pts if ≥1 responses were observed in the first stage (Simon design).
  • Ten pts received 1 prior therapy (systemic therapy in 3 pts), 15 pts had metastatic disease at baseline, 11 pts had cirrhosis, 26 pts had alpha-fetoprotein (AFP) >20.
  • Accrual is ongoing in the second stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Tanabe G, Ueno S, Maemura M, Kihara K, Aoki D, Yoshidome S, Ogura Y, Hamanoue M, Aikou T: Favorable quality of life after repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology; 2001 Mar-Apr;48(38):506-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable quality of life after repeat hepatic resection for recurrent hepatocellular carcinoma.
  • BACKGROUND/AIMS: The appropriate choice of treatment for recurrent hepatocellular carcinoma after hepatic resection remains controversial.
  • The aim of this study is to clarify prognostic factors and quality of life in patients with tumor recurrence after hepatic resection for hepatocellular carcinoma.
  • METHODOLOGY: We retrospectively analyzed 188 patients with hepatocellular carcinoma who underwent curative hepatic resection between 1988 and 1997.
  • Furthermore, quality of life after treatment for recurrence was compared between patients with repeat hepatic resection or hepatic arterial infusion chemotherapy.
  • RESULTS: In 123 patients with recurrence, unfavorable predictors after recurrence are pTNM Stage III/IV at initial surgery, receiving chemotherapy before initial surgery and presence of extrahepatic recurrence.
  • The incidence of deteriorated performance status in the repeat hepatic resection group was lower than in the hepatic arterial infusion chemotherapy group because of better psychological function in patients undergoing repeat hepatic resection.
  • CONCLUSIONS: Repeat hepatic resection provides a good prognosis and a favorable quality of life in patients with recurrence after hepatic resection for hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379343.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


18. Ochiai T, Sonoyama T, Ikoma H, Kuriu Y, Nakanishi M, Kubota T, Kikuchi S, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Kokuba Y, Otsuji E: Salvage surgery for uncontrollable hepatocellular carcinoma treated with repeated non-surgical therapies. Hepatogastroenterology; 2010 Jul-Aug;57(101):858-64
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery for uncontrollable hepatocellular carcinoma treated with repeated non-surgical therapies.
  • BACKGROUND/AIMS: Some hepatocellular carcinoma (HCC) cases undergo surgery because tumor progression cannot be controlled by various non-surgical therapies.
  • METHODOLOGY: Among cases with solitary small HCCs (< or = 3.0cm at the time of detection), the clinicopathologic features of 7 patients who had undergone hepatectomy after various non-surgical therapies (Salvage (S) group) were analyzed and compared with those of 30 patients who received hepatectomy as the initial treatment (Control (C) group).
  • RESULTS: In S group, the serum alpha-fetoprotein level was higher (p = 0.045) and macroscopic ductal invasion was more common (p = 0.028) at the time of the operation.
  • Lobectomy was more commonly performed (p = 0.034) and curability B (No residual cancer, but Stage III or IV) was more frequent (p = 0.011).
  • The survival time after the initial treatment (post-initial treatment survival) was worse (p = 0.028).
  • Univariate analyses revealed that those with maximum tumor sizes of > 3.0 cm at the time of the operation were significantly worse compared with the other patients (p = 0.012).
  • CONCLUSIONS: The timing for changing from a non-surgical treatment to a surgical treatment is important.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Salvage Therapy
  • [MeSH-minor] Aged. Catheter Ablation. Chemoembolization, Therapeutic. Disease Progression. Female. Hepatic Duct, Common / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033242.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB: Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg; 2008 Oct;248(4):617-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
  • PURPOSE: To evaluate outcomes of downstaging patients with advanced (American liver tumor study group stage III/IV) hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) to allow eligibility for orthotopic liver transplant (OLT).
  • Seventy-six (37.6%) patients with stage III/IV HCC were potential transplant candidates if downstaging was achieved by TACE.
  • Seventeen of 76 (22.4%) patients who met other qualifications underwent OLT after successful downstaging (13/38 stage III;4/38 stage IV).
  • CONCLUSION: Selected patients with stage III/IV HCC can be downstaged to Milan criteria with TACE.
  • Importantly, patients who are successfully downstaged and transplanted have excellent midterm disease-free and overall survival, similar to stage II HCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Liver Transplantation / methods. Neoplasm Staging. Preoperative Care / methods
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Follow-Up Studies. Humans. Injections, Intra-Arterial. Neoadjuvant Therapy / methods. Retrospective Studies. Treatment Outcome


20. Lin AY, Fisher GA, So S, Tang C, Levitt L: Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol; 2008 Feb;31(1):84-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib in unresectable hepatocellular carcinoma.
  • BACKGROUND: The expression of platelet-derived growth factor, a potent mitogen, and its receptor both in tissue and serum correlate with the severity of liver cirrhosis.
  • Over-expression of platelet-derived growth factor has been demonstrated in human hepatocellular carcinoma (HCC) tumors and cell lines.
  • Metastatic disease (American Joint Committee on Cancer stage IV) was noted in 13 patients and locally advanced (stage III) in the remainder.
  • Two patients had grade 3 elevated liver function tests during treatment; otherwise, there was no other grade 3 or 4 nonhematologic toxicity noted.
  • CONCLUSION: Although toxicities were tolerable, imatinib as a monotherapy for the treatment of unresectable HCC has little, if any, significant efficacy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Female. Heart Neoplasms / drug therapy. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Humans. Imatinib Mesylate. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376233.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


21. Castaldo ET, Pinson CW: Liver transplantation for non-hepatocellular carcinoma malignancy. HPB (Oxford); 2007;9(2):98-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for non-hepatocellular carcinoma malignancy.
  • Liver transplantation (LT) for hepatocellular carcinoma is effective for selected patients.
  • For CCA, series that did not emphasize highly selected early stage disease and neoadjuvant or adjuvant chemoradiation had an average 5-year survival of 10%.
  • However, emphasizing neoadjuvant radiation and chemosensitization in operatively confirmed stage I or II hilar CCA has led to improved 5-year survival, up to 82%.
  • LT is indicated under strict research protocols at selected centers, for patients with early stage CCA and anatomically unresectable (Bismuth type IV) lesions.
  • HB is typically sensitive to cisplatin-based chemotherapy.
  • LT plays a role as primary surgical therapy for those individuals in whom tumors remain unresectable after chemotherapy or as rescue therapy for those who are incompletely resected, recur after resection, or develop hepatic insufficiency after chemotherapy and/or resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Ann Surg. 1988 Apr;207(4):373-9 [2451484.001]
  • [Cites] Ann Surg. 1989 Jan;209(1):88-98 [2535924.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):483-7 [8591077.001]
  • [Cites] Hepatology. 1996 May;23(5):1105-11 [8621141.001]
  • [Cites] Ann Surg. 1997 Apr;225(4):347-54 [9114792.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):62-70 [9627173.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):358-64 [9783781.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1307-12 [9846513.001]
  • [Cites] Liver Transpl. 2000 May;6(3):317-9 [10827232.001]
  • [Cites] Transplantation. 2000 Apr 27;69(8):1633-7 [10836374.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):795-804 [10839879.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S23-9 [11084081.001]
  • [Cites] Liver Transpl. 2001 Dec;7(12):1023-33 [11753904.001]
  • [Cites] J Pediatr Surg. 2002 Feb;37(2):240-5 [11819207.001]
  • [Cites] Transplantation. 2002 Feb 15;73(3):386-94 [11884935.001]
  • [Cites] World J Surg. 2002 Aug;26(8):998-1004 [12016481.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Am J Transplant. 2002 Jul;2(6):535-8 [12118897.001]
  • [Cites] Am J Transplant. 2002 Sep;2(8):774-9 [12243499.001]
  • [Cites] Transplantation. 2002 Sep 15;74(5):652-5 [12352881.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):210-9 [14745329.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):265-71 [14745336.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):74-83 [14752798.001]
  • [Cites] Oncologist. 2004;9(1):43-57 [14755014.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):208-12 [15036197.001]
  • [Cites] J Pediatr. 2005 Feb;146(2):204-11 [15689909.001]
  • [Cites] Transplant Proc. 2005 Jun;37(5):2195-9 [15964377.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):283-4 [16041278.001]
  • [Cites] J R Soc Med. 2005 Aug;98(8):364-5 [16055903.001]
  • [Cites] Am J Transplant. 2005 Sep;5(9):2229-35 [16095502.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Semin Pediatr Surg. 2005 Nov;14(4):233-8 [16226698.001]
  • [Cites] Liver Transpl. 2005 Nov;11(11):1412-6 [16237695.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S109-12 [16286886.001]
  • [Cites] J Pediatr Surg. 2006 Jan;41(1):182-6 [16410130.001]
  • [Cites] Surgery. 1990 Dec;108(6):1091-6 [1701060.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Liver Transpl. 2000 May;6(3):309-16 [10827231.001]
  • (PMID = 18333123.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020792
  •  go-up   go-down


22. Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW: Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol; 2010 Dec;17(12):3104-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma.
  • BACKGROUND: Lack of health insurance is associated with poorer outcomes for patients with cancers amenable to early detection.
  • The effect of insurance status on hepatocellular carcinoma (HCC) presentation stage and treatment outcomes has not been examined.
  • We examined the effect of health insurance status on stage of presentation, treatment strategies, and survival in patients with HCC.
  • Logistic, Kaplan-Meier, and Cox models tested the effects of demographic and clinical covariates on the likelihood of having surgical or chemotherapeutic treatments and survival.
  • The uninsured were more likely to present with stage IV disease (P = 0.005).
  • After adjusting for demographics and tumor stage, Medicaid and uninsured patients were less likely to receive surgical treatment (both P < 0.01) but were just as likely to be treated with chemotherapy (P ≥ 0.243).
  • Survival was significantly better in privately insured patients and in those treated with surgery or chemotherapy (all P < 0.01).
  • CONCLUSIONS: Uninsured patients with HCC are more likely to present with late-stage disease.
  • Although insurance status did not affect chemotherapy utilization, Medicaid and uninsured patients were less likely to receive surgical treatment.
  • [MeSH-major] Antineoplastic Agents / economics. Carcinoma, Hepatocellular / economics. Catheter Ablation / economics. Hepatectomy / economics. Insurance, Health. Liver Neoplasms / economics. Liver Transplantation / economics
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Insurance Coverage. Male. Middle Aged. Neoplasm Staging. Registries. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Health Insurance.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585872.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / T32 HS 013833
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Kawarada Y, Yamagiwa K: [Up to date of multidisciplinary treatments centering around hepatectomy for advanced liver cancer in stage IV-A]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1489-95
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Up to date of multidisciplinary treatments centering around hepatectomy for advanced liver cancer in stage IV-A].
  • Patients with advanced Stage IV-A primary liver cancer, hepatocellular carcinoma (HCC) can be divided into subgroups: those with involvement of a major branch of the portal (Vp3) or hepatic (Vv2, Vv3) veins and those having multiple tumors in both lobes without Vp3 or Vv2, Vv3.
  • The prognosis of Stage IV-A patients with Vv2 or Vv3 may be improved by extended hepatectomy with resection and reconstruction of hepatic veins or IVC.
  • In those with Vp3, multidisciplinary treatments consisting of extended hepatectomy and adjuvant chemotherapy, i.e. intra-arterial injection or TACE, are thought to be feasible at the present, but the outcomes are still poor.
  • On the other hand, there are some Stage IV-A patients with multi-centrical tumors who have multiple tumors in both lobes without major vascular invasion, and their prognoses are improved by partial resection of each tumor.
  • However, when there are multiple tumors caused by intrahepatic metastases, multidisciplinary treatments consisting of reduction surgery, microwave ablation, ethanol injection, and intra-arterial chemotherapy might be useful at present.
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11015991.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 8
  •  go-up   go-down


24. Zhang Z, Fan S: [Liver transplantation for hepatocellular carcinoma: a report of 8 patients]. Zhonghua Wai Ke Za Zhi; 2000 Jun;38(6):415-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation for hepatocellular carcinoma: a report of 8 patients].
  • OBJECTIVE: To evaluate the feasibility of liver transplantation as a treatment for hepatocellular carcinoma (HCC).
  • TNM staging: stage II (5 cases), stage III (2 cases) and stage IV a (1 case).
  • Except for one patient who had preoperative chemotherapy, no anticancer treatment was given before and after transplantation.
  • RESULTS: Three patients had acute rejection, 5 developed complication in early post transplantation.
  • CONCLUSIONS: Liver transplantation is a feasible method for treatment of HCC in selected patients.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11832071.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Rizzetto M: Hepatocellular carcinoma: screening and therapy. Minerva Gastroenterol Dietol; 2000 Sep;46(3):143-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: screening and therapy.
  • Treatment of the liver cancer (LC) patient is often problematic as the tumour is identified at an advanced stage: the frequent coexistence of cirrhosis limits the use of surgical resection, there is no efficacious chemotherapy, and in patients treatable with liver transplant, indication is rendered uncertain from the point of view of cost-effectiveness and the high risk of recurrence of the tumour and hepatitis infection.
  • Surgical resection appears to be the treatment of choice in patients with a liver tumour in a ''healthy'' liver.
  • Nevertheless, due to the lack of organs palliative treatments, like surgical resection, PEI and TACE are the most indicated in patients with advanced neoplastic disease, in practice patients with TNM III and IV; radiotherapy with protons and the coagulation of the tumour by microwaves or laser fibres are also used in the attempt to slow down the progress of the neoplastic process.
  • In some patients the most effective approach may be the combined use of various therapies, such as TACE, PEI and surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498375.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW: Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl; 2004 Dec;10(12):1478-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
  • The efficacy of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is not well defined.
  • Univariate and multivariate analyses considered the following variables: gender, pTNM stage, tumor size, number of nodules, vascular invasion, incidental tumors, adjuvant chemotherapy, preoperative chemoembolization, alpha-fetoprotein (AFP) tumor marker, lobar distribution, and histological grade.
  • Overall survival of patients with stage I HCC was significantly better than patients with stage II, III, or IV (P < .05).
  • Eleven of 67 patients developed tumor recurrence.
  • Twenty-four of 67 patients (36%) died during the follow-up time.
  • Both univariate and multivariate analysis demonstrated that pTNM status (I versus II, III, and IV; P < .05) was a reliable prognostic indicator for patient survival.
  • Multivariate analysis showed that pretransplant chemoembolization and adjuvant chemotherapy reduced risk of death after OLT in HCC recipients.
  • Advanced tumor stage, and particularly vascular invasion, are poor prognostic indicators for tumor recurrence.
  • Early pTNM stage, adjuvant chemotherapy, and preoperative chemoembolization were associated with positive outcomes for patients who underwent OLT for concomitant HCV and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Carcinoma, Hepatocellular / virology. Hepatitis C / complications. Liver Neoplasms / surgery. Liver Neoplasms / virology. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Blood Vessels / pathology. Cause of Death. Chemoembolization, Therapeutic. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Predictive Value of Tests. Preoperative Care. Prognosis. Risk Factors. Survival Analysis


27. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, Prabhakaran PS, Benson AB: A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol; 2005 Jul-Sep;26(3):115-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.
  • The primary objective of this study was to determine the response rates of a combination of gemcitabine and cisplatin in unresectable hepatocellular carcinoma (HCC) in Indian patients.
  • The secondary objectives were to evaluate the toxicity, time to progressive disease and overall survival for this combination.
  • Chemonaive patients with histopathologically proven, bidimensionally measurable, stage Ill or IV unresectable HCC were enrolled into this study.
  • Response assessment was done by a Computed Tomography scan after every two cycles of chemotherapy.
  • The median time to progression was 18 weeks (range 1 to 74 weeks) and the median duration of response was 13 weeks (range 4 to 68 weeks).
  • There is a need to further evaluate this combination in order to define its role in the treatment of HCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512457.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L: A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs; 2008 Aug;26(4):381-6
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.
  • Pemetrexed has demonstrated activity in hepatocellular carcinoma (HCC) cell lines, and has a manageable toxicity profile in clinical trials, suggesting its potential as a treatment for HCC patients.
  • Patients premedicated with folic acid, vitamin B(12), and dexamethasone were administered pemetrexed 600 mg/m(2) IV on day 1 of each 21-day cycle until disease progression.
  • This nonrandomized study employed Simon's 2-stage design, enrolling 21 eligible patients in the first stage, stopping accrual if < or =2 responders were observed.
  • Thirteen patients died on-study: 12 PD and one liver failure; none were drug-related.
  • The planned second stage was cancelled, and the trial was closed owing to lack of response.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dexamethasone / therapeutic use. Disease Progression. Female. Folic Acid / therapeutic use. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pemetrexed. Survival Rate. Treatment Outcome. Vitamin B 12 / therapeutic use

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Chemotherapy. 2008;54(1):1-8 [18063861.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):56-62 [15655939.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S218-24 [15508087.001]
  • [Cites] World J Gastroenterol. 2007 Dec 28;13(48):6553-7 [18161926.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1955-60 [9951847.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):427-32 [10501918.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1172-8 [16803502.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2675-83 [17473199.001]
  • [Cites] Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25 [17103105.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):578-86 [15274071.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3652-9 [17575230.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):395-9 [9815697.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):421-7 [11905412.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):409-18 [15231247.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):105-10 [10412943.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1213-6 [2446752.001]
  • [Cites] J Clin Gastroenterol. 2007 Oct;41(9):839-54 [17881931.001]
  • (PMID = 18305899.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 7S5I7G3JQL / Dexamethasone; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


29. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M: Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract; 2010 Jul;64(8):1034-41
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is a complicated condition influenced by multiple confounding factors, making optimum patient management extremely challenging.
  • Ethnicity, stage at diagnosis, comorbidities and tumour morphology affect outcomes and vary from region to region, and there is no common language to assess patient prognosis and make treatment recommendations.
  • Non-surgical treatments include ablation, transarterial chemoembolisation and the multikinase inhibitor, sorafenib, but their effects in all patient subgroups are not known and further information is needed to optimise the use of these treatments.
  • AIMS: The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study (ClinicalTrials.gov identifier NCT00812175; http://clinicaltrials.gov/) is an ongoing global, prospective, non-interventional study of patients with unresectable HCC who are eligible for systemic therapy and for whom the decision has been taken to treat with sorafenib under real-life practice conditions.
  • DISCUSSION: This study will recruit 3000 patients from > 40 countries and follow them for approximately 5 years to compile a large and robust database of information that will be used to analyse local, regional and global differences in baseline characteristics, disease aetiology, treatment practice patterns and treatment outcomes, with a view to improve the knowledge base used to guide physician treatment decisions and to improve patient outcomes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Clinical Trials as Topic / methods. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Clinical Trials, Phase IV as Topic / methods. Humans. Niacinamide / analogs & derivatives. Patient Selection. Phenylurea Compounds. Prospective Studies. Research Design. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47 [16696801.001]
  • [Cites] Keio J Med. 2009 Sep;58(3):161-75 [19826210.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55 [19759364.001]
  • [Cites] Korean J Radiol. 2009 Sep-Oct;10(5):425-34 [19721826.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):159-65 [17953709.001]
  • [Cites] Clin Ther. 2007 Jun;29(6 Pt 1):1284-92 [18036390.001]
  • [Cites] Ann Intern Med. 2007 Oct 16;147(8):W163-94 [17938389.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • (PMID = 20642705.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00812175
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2905618
  •  go-up   go-down


30. Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, Suga T, Kawashima H, Togashi K, Seo S, Kitamura K, Takada Y, Uemoto S: FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging; 2010 Mar;37(3):468-82
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.
  • PURPOSE: To elucidate the prognostic role of post-therapeutic (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET), we conducted a retrospective cohort study analysing the clinical factors that affect overall survival after non-operative therapy for unresectable hepatocellular carcinoma (HCC).
  • METHODS: Sixty-seven cases with unresectable HCC who received non-operative therapy (transcatheter arterial chemoembolization: n = 24, transcatheter arterial infusion chemotherapy: n = 31, radiofrequency ablation: n = 5 or systemic chemotherapy: n = 7) and had received FDG PET for the evaluation of the therapeutic effect within 1 month after the end of the therapy were evaluated.
  • Overall survival rate was evaluated using the univariate and multivariate analyses of relevant clinical and laboratory parameters before and after therapy, including visual PET analysis and quantitative analysis using maximum standardized uptake value (SUV).
  • RESULTS: Visual PET diagnosis of post-therapeutic lesions was a good predictor of overall survival of unresectable HCC patients.
  • Multivariate analysis showed four significant prognostic factors for the survival: post-therapeutic alpha-fetoprotein (alphaFP) level (=400 ng/ml, p = 0.004), post-therapeutic visual PET diagnosis (p = 0.006), post-therapeutic clinical stage (UICC stage IV, p = 0.04) and post-therapeutic Milan criteria (p = 0.03), while pre-therapeutic clinical factors, SUV by post-therapeutic FDG PET (5.0 or more) or others did not show significance.
  • CONCLUSION: The present study suggests that post-therapeutic PET performed within 1 month after non-operative therapy can be a good predictor of overall survival in unresectable HCC patients, while pre-therapeutic evaluation including PET, tumour markers and clinical staging may not be useful.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Fluorodeoxyglucose F18. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Biological Transport. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):483. Takada, Yasuji [corrected to Takada, Yasutsugu]; Kamimoto, Shinji [corrected to Uemoto, Shinji]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6 [14696485.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1877-80 [11419843.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S7-12 [1333912.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1811-7 [7562048.001]
  • [Cites] J Hepatol. 2000 May;32(5):792-7 [10845666.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Dec;4(12):1528-36 [17162244.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):761-80 [16713550.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):344-9 [12902882.001]
  • [Cites] Dig Dis. 2001;19(4):269-78 [11935086.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1241-8 [16883000.001]
  • [Cites] J Nucl Med. 1992 Mar;33(3):333-9 [1311035.001]
  • [Cites] Nuklearmedizin. 1998;37(8):279-85 [9868710.001]
  • [Cites] J Gastroenterol. 2007 Dec;42(12):962-8 [18085353.001]
  • [Cites] Gut. 2002 Oct;51(4):459-62 [12235060.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):983-95 [15937310.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17 (3):190-7 [17591566.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):325-31 [12594668.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):1059-66 [16741317.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3314-9 [10566736.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):528-38 [18242076.001]
  • [Cites] Arch Surg. 1998 May;133(5):510-5; discussion 515-6 [9605913.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1323-9 [18347794.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):427-33 [17255262.001]
  • [Cites] J Nucl Med. 1994 Dec;35(12 ):1965-9 [7989978.001]
  • [Cites] Semin Nucl Med. 2004 Jul;34(3):209-23 [15202102.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] World J Surg. 2006 Sep;30(9):1736-41 [16850145.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5366-72 [17088570.001]
  • [Cites] Ann Nucl Med. 2003 Jun;17 (4):261-79 [12932109.001]
  • [Cites] Transpl Int. 2003 Feb;16(2):115-22 [12595973.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(1):67-76 [12918460.001]
  • [Cites] Liver Transpl. 2007 Dec;13(12):1637-44 [18044766.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18489-94 [10764804.001]
  • [Cites] Transplant Proc. 1994 Dec;26(6):3557-60 [7998274.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):439-45 [19064982.001]
  • (PMID = 19838700.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


31. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC: Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol; 2002 Jun 15;20(12):2789-97
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
  • PURPOSE: To determine surgical resectability, event-free survival (EFS), and toxicity in children with hepatocellular carcinoma (HCC) randomized to treatment with either cisplatin (CDDP), vincristine, and fluorouracil (regimen A) or CDDP and continuous-infusion doxorubicin (regimen B).
  • After initial surgery or biopsy, children with stage I (n = 8), stage III (n = 25), and stage IV (n = 13) HCC were randomly assigned to receive regimen A (n = 20) or regimen B (n = 26).
  • Patients with stage I, III, and IV had 5-year EFS estimates of 88% (SD = 12%), 8% (SD = 5%), and 0%, respectively.
  • Events occurred before postinduction surgery I in 18 (47%) of 38 patients with stage III or IV disease, and tumor resection was possible in two (10%) of the remaining 20 children with advanced-stage disease after chemotherapy.
  • CONCLUSION: Children with initially resectable HCC have a good prognosis and may benefit from the use of adjuvant chemotherapy.
  • Outcome was uniformly poor for children with advanced-stage disease treated with either regimen.
  • New therapeutic strategies are needed for the treatment of advanced-stage pediatric HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Neoplasm Staging. Prognosis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065555.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA092049
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Teratani T, Shiina S, Obi S, Hamamura K, Koike Y, Akamatsu M, Fujishima T, Tateishi R, Imai Y, Shiratori Y, Omata M: [Percutaneous tumor ablation therapy for the advanced stage of HCC]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1496-500
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Percutaneous tumor ablation therapy for the advanced stage of HCC].
  • We have performed percutaneous tumor ablation (PTA) including percutaneous ethanol injection therapy (PEIT) for 90% of the patients with hepatocellular carcinoma.
  • Since 5 years survival rate in stage IV-A reached 24.4%, the patients of stage IV-A may be considered to have an indication for PTA.
  • We have confirmed the effectiveness of the local treatment including radiotherapy for advanced hepatocellular carcinoma with portal vein invasion.
  • We are attempting to perform PTA for the extra-hepatic lesions that had no indication of other treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Catheter Ablation. Ethanol / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11015992.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


33. Brůha R, Drastich P, Hůlek P, Lata J, Petrtýl J, Procházka J, Spicák J, Vanásek T, Volfová M, Zdenek P, Portal Hypertension Working Group of the Czech Hepatology Society, J.E. Purkinje Czech Medical Society: [Diagnostics and treatment of hepatocellular carcinoma. Recommendations of the Portal Hypertension Working Group of the Czech Hepatology Society and the J.E. Purkinje Czech Medical Society ]. Vnitr Lek; 2005 Dec;51(12):1406-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostics and treatment of hepatocellular carcinoma. Recommendations of the Portal Hypertension Working Group of the Czech Hepatology Society and the J.E. Purkinje Czech Medical Society ].
  • Hepatocellular carcionma (HCC) is almost exclusively associated with liver cirrhosis as a significant HCC risk marker in advanced countries.
  • Applicable therapy depends on early diagnosis, and risk patients should be screened for the presence of HCC on a regular basis.
  • There are 3 basic curative therapies for the early stage of HCC: liver transplantation, surgical resection and different methods of local destruction of tumour (i.e., ethanolisation, thermoablation, etc.).
  • Patients at medium stage of HCC may profit from chemoembolisation.
  • Current available systemic chemotherapy is ineffective.
  • Patient survival prognosis after the application of one of the above treatment methods may be similar with that for HCC free cirrhosis patients, however, prognosis for advanced HCC patients is bad, with survival period from one to nine months.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy

  • Genetic Alliance. consumer health - Portal hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430109.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Czech Republic
  •  go-up   go-down


34. Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L: A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs; 2008 Jun;26(3):265-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
  • Hepatocellular carcinoma (HCC) remains a lethal treatment-resistant cancer with a median survival of <6 months in patients not considered candidates for radical surgical treatments.
  • A non-randomized, non-blinded multicentre two-stage phase II study was completed examining the efficacy, toxicity, and pharmacokinetics of SB-715992 at 18 mg/m2 IV q 3 weeks, in patients with measurable locally advanced, metastatic or recurrent HCC.
  • Seven (46%) patients had a best response of stable disease at the 8-week evaluation (median duration 3.9 months) Median time to progression was 1.61 months (95%CI = 1.31-3.94 months) SB-715992 plasma concentrations were comparable to those observed in the phase I studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzamides / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression. Humans. Infusions, Intravenous. Kinesin / antagonists & inhibitors. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):127-34 [12735134.001]
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Hepatology. 2000 Sep;32(3):679-80 [10991637.001]
  • [Cites] Curr Opin Pharmacol. 2001 Aug;1(4):370-7 [11710735.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):531-40 [1356418.001]
  • [Cites] Science. 2000 Apr 7;288(5463):88-95 [10753125.001]
  • [Cites] Semin Liver Dis. 1999;19(3):311-22 [10518310.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):97-105 [10077227.001]
  • [Cites] Expert Opin Pharmacother. 2003 Dec;4(12):2175-85 [14640916.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):479-83 [2839280.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1094-101 [10694562.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • (PMID = 18196204.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / KIF11 protein, human; 0 / Quinazolines; BKT5F9C2NI / ispinesib; EC 3.6.4.4 / Kinesin
  •  go-up   go-down


35. Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, Iannitti D, Kennedy T: Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol; 2010 Feb;33(1):43-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study.
  • PURPOSE: We performed a phase I study to evaluate the feasibility and determine the maximally tolerated dose of hepatic arterial infusion (HAI) of oxaliplatin in advanced hepatocellular carcinoma (HCC).
  • The therapy was continued until disease progression or excessive toxicity not amenable to appropriate modifications.
  • Stage distribution was as follows: stage II, 3 patients; stage III, 12 patients; and stage IV, 8 patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Hepatic Artery. Liver Neoplasms / drug therapy. Organoplatinum Compounds / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687731.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


36. Pham TH, Iqbal CW, Grams JM, Zarroug AE, Wall JC, Ishitani MB, Nagorney DM, Moir C: Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surg; 2007 May;42(5):834-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the most common primary liver cancers in children.
  • Forty-five (87%) received primary or neoadjuvant and/or adjuvant chemotherapy.
  • Patients had the following CCG/POG stages: I (n = 31, 60%), II (n = 6, 11.5%), III (n = 9, 17%), and IV (n = 6, 11.5%).
  • Complete gross resection (stage I and II) was achieved in 37 (71%) patients.
  • CONCLUSION: Complete resection of the pediatric primary liver tumors remains the cornerstone of treatment to achieve cure.
  • Liver transplantation in conjunction with chemotherapy may have an increasing role in the management of locally advanced primary liver cancers.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Hepatoblastoma / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Child. Child, Preschool. Combined Modality Therapy. Hepatectomy. Humans. Liver Transplantation. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502194.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Tanisaka Y, Seike H, Matsumoto T, Tanaka Y, Tsubouchi E, Miyauchi S, Iwakawa K, Ichikawa M: [A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1761-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN].
  • Results of close examination revealed stage IV B with bone metastases, and pulmonary metastases was diagnosed.
  • After consultation, whole-body chemotherapy combining S-1 and PEG-IFN was attempted as of June 26, 2007.
  • S-1 (80 mg/day) was then administered every day for two weeks with drug withdrawal for one week.
  • The therapeutic effectiveness of this chemotherapy was confirmed by imaging test.
  • The course was favorable, and whole-body chemotherapy was discontinued on January 29, 2008.
  • This treatment method is a promising choice for whole-body chemotherapy for advanced hepatocarcinoma in the future.
  • We have added some review of the literature, and the S-1+PEG-IFN combination chemotherapy is reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Polyethylene Glycols / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Angiography. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Drug Combinations. Hepatitis C, Chronic / complications. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838044.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 30IQX730WE / Polyethylene Glycols; 5VT6420TIG / Oxonic Acid; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


38. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R: Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer; 2006;37(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Combined hepatocholangiocarcinoma (CHCC) is an infrequent primary hepatic malignancy with no clearly defined diagnostic criteria, poorly studied natural history, and no guidelines regarding therapy.
  • Early TNM stage (I and II) compared with advanced disease (III and IV) correlated with higher overall survival on univariate analyses [37 and 6 mo respectively (p = 0.011)].
  • Median overall survival was significantly higher in patients who underwent potentially curative resection (23 mo, range 4-48+) compared with patients who underwent non-surgical therapies such as transcatheter arterial chemoembolization and chemotherapy (2 mo, range 1-8) (p = 0.0357, one-sided exact log-rank test).
  • Surgical resection and early stage at diagnosis predict longer survival.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Cholangiocarcinoma / complications. Liver Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1996 Oct;149(4):1167-75 [8863666.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):292-8 [15288479.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Surg Clin North Am. 1999 Feb;79(1):43-57, viii [10073181.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):643-57 [15062666.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):742-8 [9630182.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Histopathology. 1989 May;14(5):503-13 [2472345.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2000 Jul;491:1-412 [12563349.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1157-62 [15788587.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):56-60 [14745254.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Feb 25;52(2):155-63 [1313961.001]
  • [Cites] Liver. 2002 Feb;22(1):43-50 [11906618.001]
  • [Cites] Jpn J Cancer Res. 1996 Oct;87(10):1056-62 [8957064.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):35-41 [11748452.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):965-6 [10580599.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1978 Jun;9(2):215-9 [214874.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S38-44 [1333907.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2002 May;(504):1-357 [12087420.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] J Agric Food Chem. 2000 Aug;48(8):3620-32 [10956160.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):120-5 [15701504.001]
  • [Cites] Chir Ital. 1999 Jan-Feb;51(1):1-7 [10514910.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):738-43 [11710692.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1992 Jun;30(6):342-5, 382 [1337514.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):298-304 [14739102.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • [Cites] Gan To Kagaku Ryoho. 1993 Feb;20(2):295-8 [8382037.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):191-211, v [15831268.001]
  • (PMID = 17290078.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  • [Number-of-references] 37
  •  go-up   go-down


39. Ferenci P: Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol Dietol; 2006 Jun;52(2):157-74
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future.
  • The majority of those infected with the virus develop chronic progressive liver disease that over time can result in cirrhosis, end-stage liver disease, hepatocellular carcinoma and death.
  • The goal of treatment is viral eradication.
  • The recognised standard of care for chronic hepatitis C is the combination of pegylated interferon plus ribavirin, which has been shown to be effective in treatment-naïve patients, including those with persistently normal ALT levels, and in patients with HIV-HCV coinfection.
  • By far, the most important factors influencing treatment outcomes are HCV genotype and baseline HCV RNA level.
  • Customisation of therapy based on baseline factors is recommended in treatment guidelines in order to maximise cure rates.
  • Ongoing efforts to improve treatment outcomes are focused on dynamic customisation of therapy based on the on-treatment response to therapy.
  • Treatment of nonresponders to previous interferon-based therapies is an important area under investigation.
  • Although several promising oral agents have been identified and are currently in clinical development, it seems likely that pegylated interferon will remain the backbone of therapy for years to come.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Polyethylene Glycols / therapeutic use. Ribavirin / administration & dosage
  • [MeSH-minor] Drug Therapy, Combination. Forecasting. Humans. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557187.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 107
  •  go-up   go-down






Advertisement